Abstract
Hereditary hemochromatosis is a common inherited metabolic disorder of iron metabolism with variable penetrance. Portal vein thrombosis has several well-known causes including cirrhosis, myeloproliferative neoplasm, inflammatory conditions of the abdomen, intra-abdominal malignancy, intra-abdominal surgery, and thrombophilia. It is unknown whether hereditary hemochromatosis is associated with portal vein thrombosis. Material and methodology. A retrospective analysis of the National Inpatient Sample database from 2016 to 2020 was conducted using International Classification of Diseases-10 codes to identify hospitalizations with portal vein thrombosis. We used multivariate regression analysis to calculate the adjusted odds ratio after controlling for age, gender, insurance type, Charlson Comorbidity Index, cirrhosis, myeloproliferative neoplasm, inflammatory conditions of the abdomen, intra-abdominal malignancy, intra-abdominal surgery, history of past thrombosis, thrombophilia, end-stage renal disease, obesity,smoking, and hyperlipidemia. Results. There were 25805 hospitalizations with primary diagnosis of portal vein thrombosis. Multivariate logistic regression showed that hereditary hemochromatosis was independently associated with portal vein thrombosis (Odds ratio= 4.7, 95% CI=1.15 to 19.35, p-value=0.03) when cirrhosis, myeloproliferative neoplasm, inflammatory conditions of the abdomen, intra-abdominal malignancy, history of thrombosis, history of abdominal surgery, history of thrombophilia, and end-stage renal disease among other factors were controlled.
References
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343. doi:10.1002/hep.24330
Ögren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23 796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115-2119. doi:10.3748/wjg.v12.i13.2115
Quarrie R, Stawicki SP. Portal vein thrombosis: What surgeons need to know. Int J Crit Illn Inj Sci. 2018;8(2):73-77.doi:10.4103/IJCIIS.IJCIIS_71_17
Gill D, Brewer CF, Monori G, et al. Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization Study. Journal of the American Heart Association. 2019;8(15):e012994. doi:10.1161/JAHA.119.012994
HCUP-US NIS Overview. Accessed December 19, 2023. https://hcup-us.ahrq.gov/nisoverview.jsp
Ellingsen TS, Lappegård J, Ueland T, Aukrust P, Brækkan SK, Hansen JB. Plasma hepcidin is associated with future risk of venous thromboembolism. Blood Adv. 2018;2(11):1191-1197. doi:10.1182/bloodadvances. 2018018465
Day SM, Duquaine D, Mundada LV, et al. Chronic iron administración increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107(20):2601-2606. doi:10.1161/01.CIR.0000066910.02844.D0
Cooke JP. Does ADMA Cause Endothelial Dysfunction? Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(9):2032-2037. doi:10.1161/01.ATV.20.9.2032
Kenet G, Freedman J, Shenkman B, et al. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999;19(8):2017-2023. doi:10.1161/01.atv.19.8.2017
Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res. 1995;30(2):255-261.
Upchurch GR, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic Consequences of the Oxidation of Fibrinogen and their Inhibition by Aspirin. J Thromb Thrombolysis. 1998;5(1):9-14. doi:10.1023/A:1008859729045
Delval L, Brohée D, Cauchie P, Vanhaeverbeek M, Hilbert P. [Acute portal thrombosis revealing hereditary hemochromatosis: report of a case]. Rev Med Brux. 2002;23(2):83-86.
Xie YG, Lillicrap DP, Taylor SA. An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis. Blood. 1998;92(4):1461-1462.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar